Surgery alone may often be enough for asymptomatic tuberculosis lung nodules

Patients whose CT scans reveal a silent lung nodule that turns out to be tuberculosis often face a difficult question after surgery: is a course of anti-tuberculosis drugs still needed once the nodule has been completely removed? A new multicenter retrospective cohort study from China, published in BMC Pulmonary Medicine, suggests that routine postoperative drug therapy may add little measurable benefit, while exposing many patients to real treatment burdens. The findings come with important caveats, but they offer some of the clearest data yet on a question that has long lacked direct evidence.

Researchers led by Yuting Cheng, Zhixin Li and Chong Wang screened 306 patients treated at two Chinese centers between 2013 and 2024. All had undergone surgical resection of a CT-detected, symptom-free pulmonary nodule that pathology confirmed as tuberculosis. After exclusions, 273 patients entered the analysis. Of these, 228 received postoperative anti-tuberculosis therapy and 45 did not. The team tracked the primary outcome of postoperative tuberculosis recurrence over a median follow-up of 54.9 months, and also examined the secondary outcomes of medical adverse events and medication-related anxiety among treated patients.

Only four recurrences occurred during follow-up, and all four were in patients who had received drug therapy. Recurrence-free survival did not differ significantly between treated and untreated patients in the log-rank test, with a p value of 0.326. In an adjusted Firth-penalized Cox model, postoperative treatment was not significantly associated with recurrence-free survival, with a hazard ratio of 2.84 and a 95 percent confidence interval of 0.10 to 78.56, and a p value of 0.437. The authors are careful to note that the small number of events and the extremely wide confidence interval leave the direction and magnitude of the association uncertain, so the analysis cannot rule out either a modest benefit or a modest harm from postoperative drugs.

The study also identified which patients were most likely to be prescribed therapy after surgery. In multivariable logistic regression, larger lesion size was independently associated with treatment use, with an odds ratio of 1.10 per millimeter of lesion size and a 95 percent confidence interval of 1.03 to 1.16, and a p value of 0.003. A positive acid-fast staining result on the resected specimen was also independently associated with treatment use, with an odds ratio of 3.23 and a 95 percent confidence interval of 1.50 to 6.96, and a p value of 0.003. These associations suggest that clinicians in the participating centers tended to reserve postoperative drugs for patients whose nodules were larger or showed microbiological evidence of active infection.

Treatment came at a cost for many patients. Among those who received postoperative anti-tuberculosis therapy, 43.9 percent experienced treatment burden, defined in the study as medical adverse events or medication-related anxiety. Anti-tuberculosis regimens typically require months of multidrug therapy, and the study’s findings on burden underscore that the decision to treat is not risk-free even when the underlying lesion has been surgically removed. The authors conclude that routine postoperative anti-tuberculosis therapy after complete resection of asymptomatic pulmonary tuberculous nodules was not significantly associated with improved recurrence-free survival in this cohort, whereas treatment-related burden was common among treated patients.

The clinical context matters for interpreting these results. Anti-tuberculosis therapy is generally recommended for established pulmonary tuberculosis, but the incremental benefit of postoperative therapy after complete resection of an asymptomatic tuberculous nodule has remained uncertain in this specific population. Because nodules are increasingly detected incidentally on chest CT and are often removed through thoracoscopic surgery, the number of patients facing this decision has grown, and the potential treatment-related burden makes clarifying the need for postoperative therapy clinically relevant.

The authors stress that the findings do not support abandoning postoperative therapy across the board. Given the limited number of recurrence events and baseline differences between the treatment groups, they write that the results suggest postoperative observation should be considered only in carefully selected patients. The retrospective design also means treatment decisions were made by treating physicians rather than random assignment, so treated and untreated patients may have differed in ways that influenced recurrence risk. With only four events in 273 patients, the study was not powered to detect small differences in recurrence, and the wide confidence interval around the adjusted hazard ratio reflects that uncertainty.

For patients and clinicians, the practical message is that the evidence base for routine postoperative drug therapy in this population remains thin, and that the burden of therapy is substantial enough to warrant careful individualized decision-making. Larger prospective studies with more recurrence events would be needed to establish whether any subgroup of patients benefits from postoperative treatment. Until such evidence emerges, the study supports a cautious, patient-specific approach in which the risks of therapy are weighed against the uncertain and apparently small absolute risk of recurrence after complete resection.

Subject of Research: Postoperative anti-tuberculosis therapy after complete resection of asymptomatic pulmonary tuberculous nodules

Article Title: Postoperative anti-tuberculosis therapy after complete resection of asymptomatic pulmonary tuberculous nodules: a multicenter retrospective cohort study

Article References: Cheng, Y., Li, Z., Li, Z., Yao, H., Zhou, J., Han, Y., & Wang, C. (2026). Postoperative anti-tuberculosis therapy after complete resection of asymptomatic pulmonary tuberculous nodules: a multicenter retrospective cohort study. BMC Pulmonary Medicine. https://doi.org/10.1186/s12890-026-04920-w

Image Credits: AI Generated

DOI: 10.1186/s12890-026-04920-w

Keywords: tuberculosis, lung nodules, surgery, anti-tuberculosis therapy, recurrence, retrospective cohort, CT screening, treatment burden, adverse events, BMC Pulmonary Medicine, Postoperative, anti-tuberculosis